[Tissue microarrays a powerful tool in transfer and quality control in oncology].
The progress in the knowledge of molecular genetics and the availability of high-throughput technologies offer the opportunity to identify new diagnostic and prognostic markers and new therapeutic targets in human cancer. The recently developed "tissue microarraysî (TMA) technology allows parallel molecular profiling of clinical samples. Using this technique and immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), or RNA in situ hybridisation (ISH), the pathologist is now able to perform unprecedented large-scale analyses. The advantages are significant: large number of cases assessed simultaneously for numerous markers, processing in identical conditions, reduced amount of archival tissues, excellent correlation with standard methods, reduction in cost and time. This article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research.
Jacquemier
Jocelyne
J
Département d'oncologie moléculaire, Institut Paoli-Calmettes, 232, bd de Sainte-Marguerite, 13273 Marseille Cedex 9.
Ginestier
Christophe
C
Bertucci
François
F
Jauffret
Emmanuelle Charafe
EC
Geneix
Jeanine
J
Birnbaum
Daniel
D
D016208:Databases, Factual; D005784:Gene Amplification; D015870:Gene Expression; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D017404:In Situ Hybridization, Fluorescence; D009363:Neoplasm Proteins / Q000032:analysis*; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods* / Q000639:trends; D016612:Paraffin Embedding; D015203:Reproducibility of Results
D009363:Neoplasm Proteins